Name | Title | Contact Details |
---|---|---|
Bradford Cross |
Chief Technology Officer | Profile |
Bradford Cross |
Chief Technology Officer | Profile |
BH1 (Better Health for Everyone) is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.
Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.
At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms.